Skip to main content
SpringerLink
Log in

Der Stellenwert der Targeted-Therapie beim Prostatakarzinom

Value of targeted therapy for prostate cancer

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Das Prostatakarzinom ist der häufigste bösartige Tumor beim Mann. Pro Jahr sterben in Deutschland etwa 12.000 Patienten an ihrem hormonrefraktären Karzinom, obwohl die PSA-basierte Früherkennung mehr kurativ behandelbare Patienten findet. Im hormonrefraktären Stadium stehen nur limitierte therapeutische Optionen zur Verfügung. Als Standardtherapie gilt die 3-wöchentliche Docetaxel-Gabe, die einen Überlebensvorteil von etwa 2 Monaten bietet. Das zunehmende Verständnis der Signaltransduktion in den Tumorzellen bietet eine Vielzahl von möglichen Angriffspunkten für eine antineoplastische Therapie. Dabei führt die Targeted-Therapie zu einer Hemmung der Proliferation von Tumorzellen und/oder einer Hemmung der Angiogenese im Tumor. Zum jetzigen Zeitpunkt gibt es keine Rechtfertigung für Mono- oder Kombinationstherapie mit den Target-Substanzen für den routinemäßigen klinischen Einsatz.

Abstract

Prostate cancer is the most frequent malignancy of the male population. Every year in Germany approximately 12,000 patients die of their hormone-refractory prostate cancer even though early detection is able to find more curable prostate cancers. In a hormone-refractory stage we only have limited options for treatment. Although docetaxel is currently the standard of care in most hormone-refractory prostate cancers, it is not the magic therapy that will dramatically change the patient’s poor survival. This drug provides an overall survival advantage of 2 months. During recent years, significant progress has been made in the field of molecular therapy in urologic oncology. Targeted therapy leads to an inhibition of angiogenesis and proliferation in malignant tumors. Even if there is a great theoretical potential, mono- and combination therapies with target substances are not relevant in the clinical routine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Beer TM, Eilers KM et al. (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-indipendent prostate cancer. J Clin Oncol 21(1): 123–128

    Article  PubMed  CAS  Google Scholar 

  2. Boccardo F, Rubagotti A, Tacchini L et al. (2007) Gefitinib plus prednisone versus placebo plus prednisone in the treatment of hormoene-refractory prostate cancer (PRPC): A randomized phase II trial. J Clin Oncol 25: 18

    Google Scholar 

  3. Carducci MA, Padley RJ, Breul J et al. (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21(4): 679–689

    Article  PubMed  CAS  Google Scholar 

  4. Carducci MA, Saad F, Abrahamsson PA et al. (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110(9): 1959–1966

    Article  PubMed  CAS  Google Scholar 

  5. Chen CD, Welsbie DS, Tran C et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1): 33–39

    Article  PubMed  CAS  Google Scholar 

  6. Chi KN, Ellard SL, Hotte SJ et al. (2008) A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19(4): 746–751

    Article  PubMed  CAS  Google Scholar 

  7. Dahut WL, Gulley JL, Arlen PM et al. (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22(13): 2532–2539

    Article  PubMed  CAS  Google Scholar 

  8. Dahut WL, Scripture C, Posadas E et al. (2008) A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14(1): 209–214

    Article  PubMed  CAS  Google Scholar 

  9. Di Lorenzo G, Figg WD, Fossa SD et al. (2008) Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. Eur Urol (Epub ahead of print)

  10. Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 95(9): 1320–1326

    Article  PubMed  CAS  Google Scholar 

  11. Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 95(9): 1327–1335

    Article  PubMed  CAS  Google Scholar 

  12. Edwards J, Krishna NS, Grigor KM, Bartlett JM (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89(3): 552–556

    Article  PubMed  CAS  Google Scholar 

  13. Eisenberger MA, Simon R, O’Dwyer PJ et al. (1985) A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3(6): 827–841

    PubMed  CAS  Google Scholar 

  14. Guerin O, Formento P, Lo NC et al. (2008) Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 134(1): 51–57

    Article  PubMed  CAS  Google Scholar 

  15. Lin AM, Rini BI, Derynck MK et al. (2007) A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 5(5): 323–328

    Article  PubMed  CAS  Google Scholar 

  16. Lin AM, Rini BI, Weinberg V et al. (2006) A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98(4): 763–769

    Article  PubMed  CAS  Google Scholar 

  17. McDonnell TJ, Troncoso P, Brisbay SM et al. (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52(24): 6940–6944

    PubMed  CAS  Google Scholar 

  18. Petrylak DP, Tangen CM, Hussain MH et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520

    Article  PubMed  CAS  Google Scholar 

  19. Small EJ, Schellhammer PF, Higano CS et al. (2005) Results of a placebo-controlled phase II trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer(HRPC). J Clin Oncol 23: 16

    Article  Google Scholar 

  20. Tannock IF, de Wit R, Berry WR et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502–1512

    Article  PubMed  CAS  Google Scholar 

  21. Tannock IF, Osoba D, Stockler MR et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6): 1756–1764

    PubMed  CAS  Google Scholar 

  22. Tolcher AW, Chi K, Kuhn J et al. (2005) A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11(10): 3854–3861

    Article  PubMed  CAS  Google Scholar 

  23. Vogelzang NJ, Nelson JB, Schulmann CC et al. (2005) Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 23: 4563

    Google Scholar 

  24. Wu L, Birle DC, Tannock IF (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65(7): 2825–2831

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie, Uroonkologie und Kinderurologie, Universitätsklinik, Hufelandstraße 55, 45122, Essen, Deutschland

    C. Börgermann, F. vom Dorp, M. Schenck, M. Becker, J. Heß & H. Rübben

Authors
  1. C. Börgermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. vom Dorp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Schenck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Heß
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Börgermann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Börgermann, C., vom Dorp, F., Schenck, M. et al. Der Stellenwert der Targeted-Therapie beim Prostatakarzinom. Urologe 47, 1315–1319 (2008). https://doi.org/10.1007/s00120-008-1748-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-008-1748-8

Schlüsselwörter

Keywords

Search

Navigation